KDM4B: A promising oncology therapeutic target
Cancer Science · 2024-01 · 115 (1) · 8-16
DOI: 10.1111/cas.16005 ↗At a glance
Übersichtsarbeit in Cancer Science, published online on 2023-11-03. Written by Fangjing Ni and 7 co-authors. Institution: Department of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. Major MEDLINE topics: Neoplasms. Cited 15 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Epigenetic modifications are significant in tumor pathogenesis, wherein the process of histone demethylation is indispensable for regulating gene transcription, apoptosis, DNA replication, and repair of damaged DNA. The lysine demethylases (KDMs) serve an essential role in the aforementioned processes, with particular emphasis on the KDM4 family, also referred to as JMJD2. Multiple studies have underscored the significance of the KDM4 family in the regulation of various biological processes including, but not limited to, the cell cycle, DNA repair mechanisms, signaling pathways, and the progression of tumor formation. Nevertheless, it is imperative to elucidate the underlying mechanism of KDM4B, which belongs to the KDM4 gene family. This review presents a comprehensive examination of the structure, mechanism, and function of KDM4B, as well as a critical analysis of the current body of research pertaining to its involvement in tumorigenesis and development. Furthermore, this review explores the potential therapeutic strategies that specifically target KDM4B.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
ORCID profiles: Xiang Wang
Cite
APA
Ni, F., Tang, H., Cheng, S., Yu, Y., Yuan, Z., Chen, Y., Zhang, E., & Wang, X. (2024). KDM4B: A promising oncology therapeutic target. Cancer Science, 115(1), 8-16. https://doi.org/10.1111/cas.16005
Vancouver
Ni F, Tang H, Cheng S, Yu Y, Yuan Z, Chen Y, et al. KDM4B: A promising oncology therapeutic target. Cancer Science. 2024;115(1):8-16. doi:10.1111/cas.16005
BibTeX
@article{Ni2024,
author = {Ni, Fangjing and Tang, Heting and Cheng, Siteng and Yu, Yaoyu and Yuan, Zhihao and Chen, Yingfei and Zhang, Encheng and Wang, Xiang},
title = {KDM4B: A promising oncology therapeutic target},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {1},
pages = {8--16},
doi = {10.1111/cas.16005}
}
EUVIMED